

## Invitation to virtual Capital Markets Day with Xspray on June 25 at 14.00-15.30 CET

**Xspray Pharma (Nasdaq Stockholm: XSPRAY) will host a virtual Capital Market Day on June 25 at 14.00-15.30 CET. Theme of the day will be how Xspray's product candidate HyNap-Dasa can pave the way for a number of followers based on the company's technology platform. The Capital Markets Day can be seen via Xspray's website: [www.xspraypharma.com](http://www.xspraypharma.com).**

CEO Per Andersson will present Xspray's operations and the remaining development steps for HyNap-Dasa, the company's leading product candidate, until the expected submission of the ANDA application. Furthermore, Xspray's existing and potential portfolio of amorphous protein kinase inhibitors will be highlighted as well as various scenarios for how these can reach the market. VP Intellectual Property Christer Hällgren and CFO Kerstin Hasselgren will also participate in the meeting, as well as external guests with relevant experience and knowledge of this specific market.

The meeting, moderated by Charlotte Stjerngren at Cord Communications, will end with a Q&A session and studio discussion joined by external market commentators. It will be possible to submit questions to the company during the presentations via e-mail to [event@xspray.com](mailto:event@xspray.com). The meeting will be held in English.

The Capital Markets Day can be seen via Xspray's website: [www.xspraypharma.com](http://www.xspraypharma.com).  
Questions can be sent to: [event@xspray.com](mailto:event@xspray.com).

Welcome on June 25!

**For further information, please contact:**

---

Per Andersson, CEO, Xspray Pharma AB  
Phone: +46 (0) 706 88 23 48  
E-mail: [per.andersson@xspray.com](mailto:per.andersson@xspray.com)

## About Xspray Pharma

---

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company's innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 54 in December 2019. The company's leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tassigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray's HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm.

[www.xspraypharma.com](http://www.xspraypharma.com)

## Attachments

---

[Invitation to virtual Capital Markets Day with Xspray on June 25 at 14.00-15.30 CET](#)